Article
Oncology
Jennifer X. Ji, Dawn R. Cochrane, Gian Luca Negri, Shane Colborne, Sandra E. Spencer Miko, Lynn N. Hoang, David Farnell, Basile Tessier-Cloutier, Jutta Huvila, Emily Thompson, Samuel Leung, Derek Chiu, Christine Chow, Monica Ta, Martin Kobel, Lucas Feil, Michael Anglesio, Ellen L. Goode, Kelly Bolton, Gregg B. Morin, David G. Huntsman
Summary: Clear cell ovarian carcinoma (CCOC) has distinct proteomic differences compared with other subtypes of epithelial ovarian carcinoma, and potentially significant proteomic subgroups within CCOC, suggesting the possibility of stratified treatment for this cancer.
JOURNAL OF PATHOLOGY
(2022)
Review
Endocrinology & Metabolism
Haiyan Zhu, Xin Wang, Shihao Lu, Kongbo Ou
Summary: Clear cell renal cell carcinoma (ccRCC) is a malignancy characterized by metabolic reprogramming, which provides potential targets for therapeutic interventions. This review summarizes recent discoveries of metabolic alterations in ccRCC, including changes in glucose, lipid, and amino acid metabolism. It also discusses the development of metabolic drugs targeting these pathways and proposes future trends in drug development. Overall, this review highlights the potential for developing new treatments for ccRCC based on metabolic alterations.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Oncology
Sarah A. Ackroyd, David Arguello, Pilar Ramos, Haider Mahdi, Adam ElNaggar, Ira Winer, Rob Holloway, Thomas Krivak, Nathaniel Jones, Valerie Galvan Turner, Thomas Herzog, Christina Chu, Jubilee Brown, Gina Mantia-Smaldone
Summary: This study analyzed ovarian and endometrial clear cell carcinomas using comprehensive sequencing technology and compared their molecular profiles to clear cell renal cell carcinoma. The results showed that these malignancies have different mutation profiles, but ovarian and endometrial clear cell carcinomas share similar molecular features. The study also suggested that a subset of ovarian clear cell carcinoma may benefit from immunotherapy. Evaluation: 7 out of 10.
GYNECOLOGIC ONCOLOGY
(2023)
Review
Biochemistry & Molecular Biology
Jacek Rysz, Beata Franczyk, Janusz Lawinski, Anna Gluba-Brzozka
Summary: Renal cell carcinoma is a group of malignant tumors of the renal cortex. Clear cell papillary renal cell carcinoma, a specific subtype, shares morphologic and genetic features with other subtypes but also has distinct clinical behavior. Differentiating clear cell papillary renal cell carcinoma from other subtypes is crucial for appropriate management.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Multidisciplinary Sciences
Sumeyye Su, Shaya Akbarinejad, Leili Shahriyari
Summary: This study utilized digital cytometry to estimate the percentage of different immune cell types in 526 renal tumors, revealing that the most common immune cell types in clear cell renal cell carcinomas (ccRCC) tumors are CD8+ T-cells, macrophages, and CD4+ T-cells. Furthermore, unsupervised clustering analysis identified four distinct groups of ccRCC tumors based on the relative numbers of immune cells.
SCIENTIFIC REPORTS
(2021)
Article
Oncology
Giorgio Bogani, Isabelle Ray-Coquard, Nicole Concin, Natalie Y. L. Ngoi, Philippe Morice, Takayuki Enomoto, Kazuhiro Takehara, Hannelore Denys, Domenica Lorusso, Robert Coleman, Michelle M. Vaughan, Masashi Takano, Diane Provencher, Satoru Sagae, Pauline Wimberger, Robert Poka, Yakir Segev, Se Ik Kim, Jae-Weon Kim, Francisco J. Candido dos Reis, Andrea Mariani, Mario M. Leitao, Viky Makker, Nadeem Abu Rustum, Ignace Vergote, Gian Franco Zannoni, David S. P. Tan, Mary McCormack, Marta Bini, Salvatore Lopez, Francesco Raspagliesi, Pierluigi Benedetti Panici, Violante di Donato, Ludovico Muzii, Nicoletta Colombo, Giovanni Scambia, Sandro Pignata, Bradley J. Monk
Summary: Clear cell endometrial carcinoma is a rare and poorly understood cancer type. Genetic profiling can assess prognosis, with most patients characterized by p53 abnormality or NSMP type. Patients with POLE mutation have a good prognosis, while chemotherapy is effective for NSMP and p53 abnormal patients. MMRd patients may not benefit from chemotherapy, and immune checkpoint inhibitors may be more suitable for them. Further clinical trials are needed to clarify the treatment strategies for clear cell endometrial carcinoma.
GYNECOLOGIC ONCOLOGY
(2022)
Review
Oncology
Arti M. M. Raghubar, Matthew J. J. Roberts, Simon Wood, Helen G. G. Healy, Andrew J. J. Kassianos, Andrew J. J. Mallett
Summary: This review examines recent single-cell transcriptomics studies of ccRCC to clarify the transition of PTEC in ccRCC development and the immune cell types, states, and interactions that may limit the response to targeted immune therapy. It suggests stromal cells as key drivers in recurrent and locally invasive ccRCC.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nikolaos Giannakopoulos, Lars Henning, Ase Svensson, Juan Jose Badani De La Parra, Cecilia Ranhem
Summary: This report presents the CT and MRI findings of primary peritoneal clear cell carcinoma in a 53-year-old female patient. The CT scan showed a complex cystic mass with solid components, involving the right upper quadrant and displacing the liver and right kidney. The MRI revealed a multicystic mass with hemorrhage and heterogeneous solid protrusions. The diagnosis of primary peritoneal clear cell carcinoma was confirmed by histopathologic study of the surgical specimen.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
(2022)
Article
Oncology
Josiah An, Vignesh T. Packiam, Adithya Chennamadhavuni, Jordan Richards, Jayanshu Jain, Sarah L. Mott, Rohan Garje
Summary: This study assessed the incidence and survival outcomes of non-clear cell renal cell carcinoma (ccRCC) subtypes compared to ccRCC. The results showed that the survival rate was not significantly different between papillary RCC and ccRCC, while collecting duct and sarcomatoid subtypes had poorer survival outcomes. Further studies are needed to evaluate the role of neoadjuvant and adjuvant systemic therapies in improving oncologic outcomes for these subtypes.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Xiao Zhong, Xingwang Hu, Xue-Gong Fan
Summary: This study found that the prognosis of clear cell type hepatocellular carcinoma is similar to common type hepatocellular carcinoma. Tumor differentiation grade and lymph node metastasis status affect the prognosis of hepatocellular carcinoma.
Review
Biochemistry & Molecular Biology
Cesar U. Monjaras-Avila, Ana C. Lorenzo-Leal, Ana C. Luque-Badillo, Ninadh D'Costa, Claudia Chavez-Munoz, Horacio Bach
Summary: Clear cell renal cell carcinoma (ccRCC) is a kidney cancer that arises from the cells lining the kidney tubes. The tumor immune microenvironment (TIME) of ccRCC is a complex interplay of various immune cells, cytokines, and signaling pathways. The TIME of ccRCC is characterized by infiltrating immune cells, including CD8+ T cells, and an immunosuppressive environment that hinders immune cell function.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Editorial Material
Medicine, General & Internal
Katarzyna Romejko, Adam Rytel, Tomasz Rozmyslowicz, Stanislaw Niemczyk
Summary: Renal cell carcinoma (RCC) is a common genitourinary cancer, with clear cell renal cell carcinoma (ccRCC) being the most common histologic type. The incidence of ccRCC diagnosis has rapidly increased due to the development of imaging methods. However, a significant proportion of patients are already at metastatic stage at the time of diagnosis, with metastases commonly found in the lungs, bones, and liver. Metastasis of ccRCC to the heart is rare, and we present a rare case of ccRCC with heart tissue metastases visualized in transthoracic echocardiography.
Review
Oncology
Adam M. Kase, Daniel J. George, Sundhar Ramalingam
Summary: Biological discoveries in the past two decades have revolutionized the treatment of renal cell carcinoma. The development of agents targeting pro-angiogenic pathways and immunogenicity have significantly impacted the management of clear cell renal cell carcinoma. Clear cell is the most common subtype, and therapies have focused on the Von Hippel Lindau gene alterations, leading to the approval of tyrosine kinase inhibitors and immune checkpoint inhibitors. Combinations of these treatments have become the standard of care for advanced clear cell renal cell carcinoma, with promising new therapeutic targets under development.
Article
Medicine, General & Internal
Jesus Miranda-Poma, Lucia Trilla-Fuertes, Rocio Lopez-Vacas, Elena Lopez-Camacho, Eugenia Garcia-Fernandez, Ana Pertejo, Maria Lumbreras-Herrera, Andrea Zapater-Moros, Mariana Diaz-Almiron, Antje Dittmann, Juan Angel Fresno Vara, Enrique Espinosa, Pilar Gonzalez-Peramato, Alvaro Pinto-Marin, Angelo Gamez-Pozo
Summary: This study aimed to explore the tumor proteome of patients diagnosed with localized clear cell renal cancer (ccRCC) and treated with surgery. A total of 165 FFPE tumor samples were analyzed, leading to the identification and quantification of 3091 proteins. Two proteomics subtypes of ccRCC (CC1 and CC2) were identified, each characterized by specific protein expression patterns and functional features. The knowledge gained from this study could potentially aid in the development of new drugs targeting subtype-specific deregulated pathways.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Oncology
Yongheng Deng, Shaoliang Zhu, Wen Yan, Lunan Qi, Zushun Chen, Liang Ma
Summary: Patients with primary clear cell carcinoma of the liver (PCCCL) have better survival rates compared to patients with other types of hepatocellular carcinoma. Factors such as AFP level, tumor size, liver cirrhosis, and portal vein tumor thrombosis are risk factors for disease-free survival (DFS), while tumor size, capsule formation, and Ki-67 are risk factors for overall survival (OS). Satellite nodules are protective factors for both DFS and OS.